{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:30Z","timestamp":1792271370400,"version":"4.4.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is a clinical disorder characterized by aberrant plasma cell growth in the bone marrow microenvironment. Globally, the prevalence of MM has been steadily increasing at an alarming rate. In the United States, more than 30,000 cases will be diagnosed in 2024 and it accounts for about 2% of cancer diagnoses and more than 2% of cancer deaths, more than double the worldwide figure. Both symptomatic and active MM are distinguished by uncontrolled plasma cell growth, which results in severe renal impairment, anemia, hypercalcemia, and bone loss. Multiple drugs have been approved by the FDA and are now widely used in clinical practice for MM. Although triplet and quadruplet induction regimens, autologous stem cell transplantation (ASCT), and maintenance treatment are used, MM continues to be an incurable illness characterized by relapses that may occur at various phases of its progression. MM patients with frailty, extramedullary disease, plasma cell leukemia, central nervous system recurrence, functional high risk, and the elderly are among those with the greatest current unmet needs. The high cost of care is an additional challenge. MM cells are highly protein secretary cells and thus are dependent on the activation of certain translation pathways. MM also has a high chance of altering ribosomal protein-encoding genes like MYC mutation. In this article we discuss the importance of ribosome biogenesis in promoting MM and RNA polymerase I inhibition as an upcoming treatment with potential promise for MM patients.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s10585-024-10305-2","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T19:47:25Z","timestamp":1724183245000},"page":"829-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics"],"prefix":"10.1007","volume":"41","author":[{"given":"Mohamed H.","family":"Elbahoty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavyasree","family":"Papineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev S.","family":"Samant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"11","key":"10305_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046\u20131060","journal-title":"N Engl J Med"},{"issue":"12","key":"10305_CR2","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","volume":"108","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A et al (2023) Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica 108(12):3384\u20133391","journal-title":"Haematologica"},{"issue":"1","key":"10305_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K et al (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606","journal-title":"BMC Cancer"},{"issue":"1","key":"10305_CR4","doi-asserted-by":"publisher","first-page":"11176","DOI":"10.1038\/s41598-024-61420-9","volume":"14","author":"CLB Andrade","year":"2024","unstructured":"Andrade CLB, Ferreira MV, Alencar BM, Junior AMA, Lopes TJS, dos Santos AS et al (2024) Enhancing diagnostic accuracy of multiple myeloma through ML-driven analysis of hematological slides: new dataset and identification model to support hematologists. Sci Rep 14(1):11176","journal-title":"Sci Rep"},{"issue":"389","key":"10305_CR5","doi-asserted-by":"publisher","first-page":"eaal2668","DOI":"10.1126\/scitranslmed.aal2668","volume":"9","author":"S Manier","year":"2017","unstructured":"Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ et al (2017) Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med 9(389):eaal2668","journal-title":"Sci Transl Med"},{"issue":"1","key":"10305_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR (2023) Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch 482(1):163\u2013177","journal-title":"Virchows Arch"},{"issue":"2","key":"10305_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14740\/wjon1245","volume":"11","author":"BR Madhira","year":"2020","unstructured":"Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K et al (2020) Recent advances in the management of smoldering multiple myeloma. World J Oncol 11(2):45\u201354","journal-title":"World J Oncol"},{"key":"10305_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/BLCTT.S272703","volume":"13","author":"M Hussain","year":"2023","unstructured":"Hussain M, Yellapragada S, Al HS (2023) Differential diagnosis and therapeutic advances in multiple myeloma: a review article. Blood Lymphat Cancer 13:33\u201357","journal-title":"Blood Lymphat Cancer"},{"issue":"5","key":"10305_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477","journal-title":"JAMA"},{"issue":"8","key":"10305_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107","journal-title":"Am J Hematol"},{"issue":"2","key":"10305_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/cells10020336","volume":"10","author":"IJ Cardona-Benavides","year":"2021","unstructured":"Cardona-Benavides IJ, de Ram\u00f3n C, Guti\u00e9rrez NC (2021) Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells 10(2):336","journal-title":"Cells"},{"issue":"7","key":"10305_CR12","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A et al (2022) Multiple myeloma with t(11; 14): unique biology and evolving landscape. Am J Cancer Res 12(7):2950\u20132965","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10305_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","volume":"11","author":"SA Tuazon","year":"2021","unstructured":"Tuazon SA, Holmberg LA, Nadeem O, Richardson PG (2021) A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 11(2):23","journal-title":"Blood Cancer J"},{"key":"10305_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101465","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Sun Z, Qu X (2022) Advances in the treatment of extramedullary disease in multiple myeloma. Transl Oncol 22:101465","journal-title":"Transl Oncol"},{"key":"10305_CR15","unstructured":"NCC Center (2024) Multiple myeloma 2024 (version 3.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"issue":"10","key":"10305_CR16","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"G Annamaria","year":"2020","unstructured":"Annamaria G, Kenneth CA (2020) Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica 105(10):2358\u20132367","journal-title":"Haematologica"},{"issue":"14","key":"10305_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S et al (2019) Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol 37(14):1228\u20131263","journal-title":"J Clin Oncol"},{"issue":"9","key":"10305_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S (2020) Multiple myeloma current treatment algorithms. Blood Cancer J 10(9):94","journal-title":"Blood Cancer J"},{"issue":"1","key":"10305_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","volume":"98","author":"N Burwick","year":"2019","unstructured":"Burwick N, Sharma S (2019) Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 98(1):19\u201328","journal-title":"Ann Hematol"},{"issue":"1","key":"10305_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/hematology.2022000404","volume":"2022","author":"CL Costello","year":"2022","unstructured":"Costello CL (2022) Newly diagnosed multiple myeloma: making sense of the menu. Hematology 2022(1):539\u2013550","journal-title":"Hematology"},{"issue":"7","key":"10305_CR21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/cancers15072160","volume":"15","author":"D Dima","year":"2023","unstructured":"Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A et al (2023) Management of relapsed\u2013refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers 15(7):2160","journal-title":"Cancers"},{"issue":"8","key":"10305_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"7","key":"10305_CR23","doi-asserted-by":"publisher","first-page":"A347","DOI":"10.1016\/j.jval.2016.09.2114","volume":"19","author":"X Gatopoulou","year":"2016","unstructured":"Gatopoulou X, Bardenheuer K, Van Hoorenbeeck S, Kempel A (2016) PCN42\u2014treatment patterns of relapsed and refractory multiple myeloma in Europe (EU-28). Value Health 19(7):A347\u2013A766","journal-title":"Value Health"},{"key":"10305_CR24","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.5045\/br.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim S-H (2020) Treatment of relapsed and refractory multiple myeloma. Blood Res 55:S43\u2013S53","journal-title":"Blood Res"},{"issue":"2","key":"10305_CR25","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R (2023) Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol 30(2):2322\u20132347","journal-title":"Curr Oncol"},{"issue":"3","key":"10305_CR26","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ijms23031649","volume":"23","author":"S Das","year":"2022","unstructured":"Das S, Juliana N, Yazit NAA, Azmani S, Abu IF (2022) Multiple myeloma: challenges encountered and future options for better treatment. Int J Mol Sci 23(3):1649","journal-title":"Int J Mol Sci"},{"key":"10305_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/EDBK_349603","volume":"42","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Nooka AK, Larson SM (2022) Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book 42:643\u2013654","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10305_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P et al (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12(3):45","journal-title":"Blood Cancer J"},{"issue":"8","key":"10305_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127(8):971\u2013976","journal-title":"Blood"},{"issue":"2","key":"10305_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH (2020) Multiple myeloma: available therapies and causes of drug resistance. Cancers 12(2):407","journal-title":"Cancers"},{"key":"10305_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973836","volume":"12","author":"AG Solimando","year":"2022","unstructured":"Solimando AG, Malerba E, Leone P, Prete M, Terragna C, Cavo M et al (2022) Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche. Front Oncol 12:973836","journal-title":"Front Oncol"},{"issue":"1","key":"10305_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200771","volume":"32","author":"KH Maclachlan","year":"2024","unstructured":"Maclachlan KH, Gitareja K, Kang J, Cuddihy A, Cao Y, Hein N et al (2024) Targeting the ribosome to treat multiple myeloma. Mol Ther Oncol 32(1):200771","journal-title":"Mol Ther Oncol"},{"issue":"11","key":"10305_CR33","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s12276-022-00884-z","volume":"54","author":"S-H Jung","year":"2022","unstructured":"Jung S-H, Park S-S, Lim J-Y, Sohn SY, Kim NY, Kim D et al (2022) Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness. Exp Mol Med 54(11):1967\u20131978","journal-title":"Exp Mol Med"},{"key":"10305_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcdb.2022.03.043","volume":"136","author":"C Ni","year":"2023","unstructured":"Ni C, Buszczak M (2023) The homeostatic regulation of ribosome biogenesis. Semin Cell Dev Biol 136:13\u201326","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10305_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","volume":"8","author":"L Jiao","year":"2023","unstructured":"Jiao L, Liu Y, Yu X-Y, Pan X, Zhang Y, Tu J et al (2023) Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduct Target Ther 8(1):15","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10305_CR36","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.18632\/aging.101922","volume":"11","author":"Z Turi","year":"2019","unstructured":"Turi Z, Lacey M, Mistrik M, Moudry P (2019) Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. Aging (Albany NY) 11(8):2512\u20132540","journal-title":"Aging (Albany NY)"},{"issue":"13","key":"10305_CR37","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS (2022) Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res 82(13):2344\u20132353","journal-title":"Cancer Res"},{"key":"10305_CR38","doi-asserted-by":"crossref","unstructured":"Ban Y, Zou Y, Liu Y, Lee SB, Bednarczyk RB, Sheng J et al (2024) Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer. bioRxiv","DOI":"10.7554\/eLife.89486.2"},{"key":"10305_CR39","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/blood-2021-152121","volume":"138","author":"Z Chyra","year":"2021","unstructured":"Chyra Z, Samur MK, Aktas-Samur A, Yao Y, Derebail S, Perini T et al (2021) B cell transcriptional coactivator POU2AF1 (BOB-1) is an early transcription factor modulating the protein synthesis and ribosomal biogenesis in multiple myeloma: with therapeutic implication. Blood 138:2670","journal-title":"Blood"},{"issue":"4","key":"10305_CR40","doi-asserted-by":"publisher","first-page":"463","DOI":"10.37349\/etat.2022.00095","volume":"3","author":"V Raimondi","year":"2022","unstructured":"Raimondi V, Iannozzi NT, Burroughs-Garc\u00eca J, Toscani D, Storti P, Giuliani N (2022) A personalized molecular approach in multiple myeloma: the possible use of RAF\/RAS\/MEK\/ERK and BCL-2 inhibitors. Explor Target Antitumor Ther 3(4):463\u2013479","journal-title":"Explor Target Antitumor Ther"},{"issue":"6","key":"10305_CR41","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","volume":"25","author":"WJ Chng","year":"2011","unstructured":"Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25(6):1026\u20131035","journal-title":"Leukemia"},{"issue":"8","key":"10305_CR42","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/leu.2014.70","volume":"28","author":"M Affer","year":"2014","unstructured":"Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K et al (2014) Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28(8):1725\u20131735","journal-title":"Leukemia"},{"issue":"1","key":"10305_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","volume":"14","author":"SE Ahmadi","year":"2021","unstructured":"Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14(1):121","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10305_CR44","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.devcel.2022.03.018","volume":"57","author":"N Zielke","year":"2022","unstructured":"Zielke N, V\u00e4h\u00e4rautio A, Liu J, Kivioja T, Taipale J (2022) Upregulation of ribosome biogenesis via canonical E-boxes is required for Myc-driven proliferation. Dev Cell 57(8):1024\u201336.e5","journal-title":"Dev Cell"},{"issue":"43","key":"10305_CR45","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10305_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J et al (2003) PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267\u2013273","journal-title":"Nat Genet"},{"issue":"1","key":"10305_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41698-023-00410-y","volume":"7","author":"BJ Metge","year":"2023","unstructured":"Metge BJ, Alsheikh HA, Chen D, Elhamamsy AR, Hinshaw DC, Chen BR et al (2023) Ribosome biosynthesis and Hedgehog activity are cooperative actionable signaling mechanisms in breast cancer following radiotherapy. NPJ Precis Oncol 7(1):61","journal-title":"NPJ Precis Oncol"},{"issue":"Supplement 1","key":"10305_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood-2022-162445","volume":"140","author":"K Kurata","year":"2022","unstructured":"Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J et al (2022) BRD9 is essential for ribosome biogenesis and the survival of multiple myeloma cells. Blood 140(Supplement 1):596\u2013597","journal-title":"Blood"},{"issue":"7","key":"10305_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1096\/fba.2018-00075","volume":"1","author":"V Oliveira","year":"2019","unstructured":"Oliveira V, Mahajan N, Bates ML, Tripathi C, Kim KQ, Zaher HS et al (2019) The snoRNA target of t(4; 14) in multiple myeloma regulates ribosome biogenesis. FASEB Bioadv 1(7):404\u2013414","journal-title":"FASEB Bioadv"},{"issue":"1","key":"10305_CR50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12964-024-01699-3","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, Vandewalle N, De Veirman K, Vanderkerken K, Menu E, De Bruyne E (2024) Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy. Cell Commun Signal 22(1):320","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10305_CR51","volume":"2014","author":"M Showkat","year":"2014","unstructured":"Showkat M, Beigh MA, Andrabi KI (2014) mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int 2014(1):686984","journal-title":"Mol Biol Int"},{"issue":"11","key":"10305_CR52","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3390\/biom13111593","volume":"13","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang S, Jiao Y (2023) The effects of deregulated ribosomal biogenesis in cancer. Biomolecules 13(11):1593","journal-title":"Biomolecules"},{"issue":"1","key":"10305_CR53","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS et al (2023) Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 8(1):375","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"10305_CR54","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.3390\/cancers14225520","volume":"14","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani MM et al (2022) Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy. Cancers (Basel) 14(22):5520","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10305_CR55","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbagrm.2015.02.005","volume":"1849","author":"A Gentilella","year":"2015","unstructured":"Gentilella A, Kozma SC, Thomas G (2015) A liaison between mTOR signaling, ribosome biogenesis and cancer. Biochim Biophys Acta 1849(7):812\u2013820","journal-title":"Biochim Biophys Acta"},{"issue":"22","key":"10305_CR56","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1007\/s00018-019-03231-0","volume":"76","author":"SE Weeks","year":"2019","unstructured":"Weeks SE, Metge BJ, Samant RS (2019) The nucleolus: a central response hub for the stressors that drive cancer progression. Cell Mol Life Sci 76(22):4511\u20134524","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10305_CR57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/ph17030392","volume":"17","author":"E Colarusso","year":"2024","unstructured":"Colarusso E, Chini MG, Bifulco G, Lauro G, Giordano A (2024) Identification and development of BRD9 chemical probes. Pharmaceuticals 17(3):392","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10305_CR58","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-22-3668","volume":"29","author":"K Kurata","year":"2023","unstructured":"Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J et al (2023) BRD9 degradation disrupts ribosome biogenesis in multiple myeloma. Clin Cancer Res 29(9):1807\u20131821","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10305_CR59","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/cancers16071319","volume":"16","author":"B Chowdhury","year":"2024","unstructured":"Chowdhury B, Garg S, Ni W, Sattler M, Sanchez D, Meng C et al (2024) Synergy between BRD9- and IKZF3-targeting as a therapeutic strategy for multiple myeloma. Cancers 16(7):1319","journal-title":"Cancers"},{"issue":"2","key":"10305_CR60","doi-asserted-by":"publisher","first-page":"bbae023","DOI":"10.1093\/bib\/bbae023","volume":"25","author":"Y Zang","year":"2024","unstructured":"Zang Y, Ran X, Yuan J, Wu H, Wang Y, Li H et al (2024) Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer. Brief Bioinform 25(2):bbae023","journal-title":"Brief Bioinform"},{"issue":"1","key":"10305_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjh.14525","volume":"177","author":"HC Lee","year":"2017","unstructured":"Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ et al (2017) RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. Br J Haematol 177(1):80\u201394","journal-title":"Br J Haematol"},{"issue":"6\u20137","key":"10305_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000516394","volume":"161","author":"A Datta","year":"2021","unstructured":"Datta A, Pollock KJ, Kormuth KA, Brosh RM Jr (2021) G-quadruplex assembly by ribosomal DNA: emerging roles in disease pathogenesis and cancer biology. Cytogenet Genome Res 161(6\u20137):285\u2013296","journal-title":"Cytogenet Genome Res"},{"key":"10305_CR63","doi-asserted-by":"publisher","first-page":"14432","DOI":"10.1038\/ncomms14432","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O\u2019Neil NJ et al (2017) CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat Commun 8:14432","journal-title":"Nat Commun"},{"issue":"4","key":"10305_CR64","first-page":"842","volume":"4","author":"S Mart\u00ednez-Mart\u00edn","year":"2021","unstructured":"Mart\u00ednez-Mart\u00edn S, Soucek L (2021) MYC inhibitors in multiple myeloma. Cancer Drug Resist 4(4):842\u2013865","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10305_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevi\u0107 S (2018) Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer 18(1):51\u201363","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10305_CR66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jpha.2023.10.001","volume":"14","author":"M Wang","year":"2024","unstructured":"Wang M, Vulcano S, Xu C, Xie R, Peng W, Wang J et al (2024) Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment. J Pharm Anal 14(3):308\u2013320","journal-title":"J Pharm Anal"},{"key":"10305_CR67","doi-asserted-by":"publisher","first-page":"129016","DOI":"10.1016\/j.bmcl.2022.129016","volume":"77","author":"H Xu","year":"2022","unstructured":"Xu H, Hurley LH (2022) A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex). Bioorg Med Chem Lett 77:129016","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"10305_CR68","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1038\/s41388-018-0611-7","volume":"38","author":"\u00d8H Hald","year":"2019","unstructured":"Hald \u00d8H, Olsen L, Gallo-Oller G, Elfman LHM, L\u00f8kke C, Kogner P et al (2019) Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene 38(15):2800\u20132813","journal-title":"Oncogene"},{"issue":"1","key":"10305_CR69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","volume":"25","author":"K Peltonen","year":"2014","unstructured":"Peltonen K, Colis L, Liu H, Trivedi R, Moubarek Michael S, Moore Henna M et al (2014) A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25(1):77\u201390","journal-title":"Cancer Cell"},{"issue":"1","key":"10305_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-018-0609-1","volume":"11","author":"E Derenzini","year":"2018","unstructured":"Derenzini E, Rossi A, Trer\u00e9 D (2018) Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. J Hematol Oncol 11(1):75","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10305_CR71","first-page":"1058","volume":"25","author":"A Zisi","year":"2022","unstructured":"Zisi A, Kanellis DC, Moussaud S, Karlsson I, Car\u00e9n H, Br\u00e4utigam L et al (2022) Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth. Neurooncology 25(6):1058\u20131072","journal-title":"Neurooncology"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10305-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10305-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10305-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T20:02:44Z","timestamp":1734984164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10305-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10305"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10305-2","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}